Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lorecivivint - Biosplice Therapeutics

Next Previous
Drug Profile

Lorecivivint - Biosplice Therapeutics

Alternative Names: Adavivint - Biosplice Therapeutics; SM-04690

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Samumed
  • Developer Biosplice Therapeutics
  • Class Amides; Anti-inflammatories; Antirheumatics; Fluorinated hydrocarbons; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Clk dual-specificity kinase inhibitors; DYRK kinase inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Osteoarthritis
  • Preclinical Intervertebral disc degeneration

Most Recent Events

  • 17 Oct 2025 Lorecivivint is still in preclinical trials for degenerative disc disease in the US (Intra-articular) (Biosplice Therapeutics pipeline, October 2025)
  • 14 Nov 2024 Efficacy data from a phase III trial in Knee osteoarthritis presented at the ACR Convergence 2024 (ACR-2024)
  • 12 Jul 2024 Updated efficacy and adverse events data from a phase III trial in Osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top